Home » Newsletters » BioWorld Science

BioWorld Science

June 3, 1997

View Archived Issues

Metra Biosystems' bone resorption immunoassay cleared in Japan

NIH funds development of Glyko Biomedical's lysosomal storage disease test

NIH sponsors Kosan Biosciences' research in immunology and CNS diseases

Interferon Sciences announces distribution agreement for Alferon N Injection

Identification of novel polyamine compounds with anticancer activity

CAAX-based protein farnesyltransferase inhibitors from Merck & Co.

Ludwig Institute describes new tumor rejection antigens

AGE inhibitor described by Kissei

Suntory presents new glutamate receptor antagonists

Lilly prepares new 5-HT1F agonists

Nippon Kayaku discovers new antitumor agent

Orally active antiplatelet agents described by Taisho

Tanabe Seiyaku reveals new ET antagonists

Comparative studies reported for treatment of paroxysmal atrial fibrillation

Schering-Plough's Fareston approved by the FDA

Proarrhythmia associated with cisapride; exacerbation by cytochrome P-450 inhibitors

Cell Genesys and Somatix merge

ACE inhibitors inhibit bone resorption in vitro

PPL Therapeutics reports positive phase I results for AAT

Procept completes phase I trial of PRO-2000 gel

Pharmacokinetics, efficacy and tolerability of reboxetine

Alpha Therapeutic and Techniclone report milestone in LYM-1 clinical development

Receptagen receives notice of allowance of U.S. patent for "growth blocker" technology

Neurobiological Technologies' Xerecept shows antiedema activity

RCT issued U.S. patent for azonafide compounds

NeoTherapeutics reports AIT-082 interim phase I/II results

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 19, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 19, 2025.
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.